Nagaoka, K.; Kawasuji, H.; Takegoshi, Y.; Murai, Y.; Kaneda, M.; Ueno, A.; Miyajima, Y.; Niimi, H.; Morinaga, Y.; Yamamoto, Y.
Effect of Casirivimab/Imdevimab Treatment on Serum Type I Interferon Levels in SARS-CoV-2 Infection. Viruses 2022, 14, 1399.
https://doi.org/10.3390/v14071399
AMA Style
Nagaoka K, Kawasuji H, Takegoshi Y, Murai Y, Kaneda M, Ueno A, Miyajima Y, Niimi H, Morinaga Y, Yamamoto Y.
Effect of Casirivimab/Imdevimab Treatment on Serum Type I Interferon Levels in SARS-CoV-2 Infection. Viruses. 2022; 14(7):1399.
https://doi.org/10.3390/v14071399
Chicago/Turabian Style
Nagaoka, Kentaro, Hitoshi Kawasuji, Yusuke Takegoshi, Yushi Murai, Makito Kaneda, Akitoshi Ueno, Yuki Miyajima, Hideki Niimi, Yoshitomo Morinaga, and Yoshihiro Yamamoto.
2022. "Effect of Casirivimab/Imdevimab Treatment on Serum Type I Interferon Levels in SARS-CoV-2 Infection" Viruses 14, no. 7: 1399.
https://doi.org/10.3390/v14071399
APA Style
Nagaoka, K., Kawasuji, H., Takegoshi, Y., Murai, Y., Kaneda, M., Ueno, A., Miyajima, Y., Niimi, H., Morinaga, Y., & Yamamoto, Y.
(2022). Effect of Casirivimab/Imdevimab Treatment on Serum Type I Interferon Levels in SARS-CoV-2 Infection. Viruses, 14(7), 1399.
https://doi.org/10.3390/v14071399
